FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 62 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... October 6, 2022 Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Cancer Research UK honours Her Majesty The Queen, the charity’s Patron September 8, 2022 Load more HOT NEWS Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... What to Know About 3 Common Misconceptions Around Food and Cancer... How Your Primary Care Provider Can Help You Throughout Your Cancer...
